De Novo Pharmaceuticals Ltd and Roche announce the successful creation of a comprehensive platform for de novo drug design.

(From Chemical Business NewsBase - Press Release)

De Novo Pharmaceuticals Ltd (De Novo) and Roche announced the successful completion of their technology development collaboration with the creation of SkelGen II, a radically new chemoinformatics platform to accelerate drug discovery. The collaboration brought together the two pre-eminent groups in the world of de novo drug design, in order to build upon SkelGen, De Novo's proprietary structure generator. This technology has been successfully applied to a range of different therapeutic targets for the generation of novel lead molecules. The new computational platform, SkelGen II, extends the de novo structure …